Chinese Journal of Respiratory and Critical Care Medicine
Supervisor：Ministry of Education of the People's Republic of ChinaSponsor：West China Medical Center & West China Hospital, Sichuan University Editor-in-chief：LIN Jiangtao / LIU Chuntao Publishing period：
Monthly
ISSN：1671-6205CN：51-1631/R
Citation：張娟娟, 桂賢華, 蔡后榮, 肖永龍, 邱玉英, 孟凡青, 付堯. 三例肺腫瘤血栓性微血管病的臨床、影像及病理分析. Chinese Journal of Respiratory and Critical Care Medicine, 2018, 17(5): 509-513. doi: 10.7507/1671-6205.201707049Copy
Copyright ? the editorial department of Chinese Journal of Respiratory and Critical Care Medicine of West China Medical Publisher. All rights reserved
1.
von Herbay A, Illes A, Waldherr R, et al. Pulmonary tumor thrombotic microangiopathy with pulmonary hypertension. Cancer, 1990, 66(3): 587-592.
2.
Uruga H, Fujii T, Kurosaki A. Pulmonary tumor thrombotic microangiopathy: a clinical analysis of 30 autopsy cases. Intern Med, 2013, 52(12): 1317-1323.
3.
Chinen K, Tokuda Y, Fujiwara M. Pulmonary tumor thrombotic microangiopathy in patients with gastric carcinoma: an analysis of 6 autopsy cases and review of the literature. Pathol Res Pract, 2010, 206(10): 682-689.
4.
Higo K, Kubota K, Takeda A. Successful antemortem diagnosis and treatment of pulmonary tumor thrombotic microangiopathy. Intern Med, 2014, 53(22): 2595-2599.
Higashi A, Dohi Y, Uraoka N. The potential role of inflammation associated with interaction between osteopontin and CD44 in a case of pulmonary tumor thrombotic microangiopathy caused by breast cancer. Intern Med, 2015, 54(22): 2877-2880.
7.
Takahashi F, Kumasaka T, Nagaoka T. Osteopontin expression in pulmonary tumor thrombotic microangiopathy caused by gastric carcinoma. Pathol Int, 2009, 59(10): 752-756.
Fukada I, Araki K, Kobayashi K, et al. Imatinib could be a new strategy for pulmonary hypertension caused by pulmonary tumor thrombotic microangiopathy in metastatic breast cancer. Springerplus, 2016, 5(1): 1582.
1. von Herbay A, Illes A, Waldherr R, et al. Pulmonary tumor thrombotic microangiopathy with pulmonary hypertension. Cancer, 1990, 66(3): 587-592.
2. Uruga H, Fujii T, Kurosaki A. Pulmonary tumor thrombotic microangiopathy: a clinical analysis of 30 autopsy cases. Intern Med, 2013, 52(12): 1317-1323.
3. Chinen K, Tokuda Y, Fujiwara M. Pulmonary tumor thrombotic microangiopathy in patients with gastric carcinoma: an analysis of 6 autopsy cases and review of the literature. Pathol Res Pract, 2010, 206(10): 682-689.
4. Higo K, Kubota K, Takeda A. Successful antemortem diagnosis and treatment of pulmonary tumor thrombotic microangiopathy. Intern Med, 2014, 53(22): 2595-2599.
6. Higashi A, Dohi Y, Uraoka N. The potential role of inflammation associated with interaction between osteopontin and CD44 in a case of pulmonary tumor thrombotic microangiopathy caused by breast cancer. Intern Med, 2015, 54(22): 2877-2880.
7. Takahashi F, Kumasaka T, Nagaoka T. Osteopontin expression in pulmonary tumor thrombotic microangiopathy caused by gastric carcinoma. Pathol Int, 2009, 59(10): 752-756.
10. Fukada I, Araki K, Kobayashi K, et al. Imatinib could be a new strategy for pulmonary hypertension caused by pulmonary tumor thrombotic microangiopathy in metastatic breast cancer. Springerplus, 2016, 5(1): 1582.
1/5
WeChat